CONCLUSION
Successful Haplo-HCT utilizing an Aba- based regimen can result in reliable engraftment and acceptable GVHD. Similar to other studies, this supports the concept of Aba-induced immune tolerance with minimal treatment-related morbidity. Our small sample size limits generalizability and a prospective study incorporating abatacept as upfront GVHD prophylaxis to validate these results in the haplo-HCT setting is being developed at our program. Alternatives to the PTCy regimen may be especially needed to improve outcomes for patients requiring high risk transplants, such as those undergoing a second HCT or have had significant previous toxicity.
Acknowledgment: None
Declaration of Interests: The authors declare no potential interests.